International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2022 - IJCMAS--ICV 2022: 95.28 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020] For more details click here

Login as a Reviewer

See Guidelines to Authors
Current Issues
Download Publication Certificate

Original Research Articles                      Volume : 5, Issue:12, December, 2016

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : /
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Int.J.Curr.Microbiol.App.Sci.2016.5(12): 240-255

Curcumin Boosts up the Efficacy of Imatinib Mesylate in Chronic Myelogenic Leukemia Cell Line K-562 by Modulation of Various Markers
Mukherjee1, R. Sarkar1, S. Mukherjee1, J. Biswas2 and M. Roy1*
1Department of Environmental Carcinogenesis & Toxicology, 2Director
Chittaranjan National Cancer Institute, 37, S P Mukherjee Road, Kolkata 700 026, India
*Corresponding author

Imatinib mesylate(IM) is the most commonly used drug for therapy of chronic myeloid leukemia (CML). It exerts its effect by targeting a constitutively activated tyrosine kinase Bcr-Abl, a characteristic feature of CML. This anti-tumor drug also influences various other proteins like cytokines, transcription factors and their associated signalling pathways that contribute to the development of leukemogenesis. However, it poses serious side effects. Thus attention should be given to non-toxic means of leukemia control. Phytochemicals like curcumin possess a plethora of anti-cancer properties, show minimal toxicity and may therefore come to the rescue. The present study aims to explore the potential of curcumin to boost up the efficacy of IM, and to minimize the drug dose and associated toxicity in human chronic myelogenous leukemia cell line K-562. The drug IM was found to modulate the expression of markers deregulated in CML. However, curcumin refines the efficacy of IM, especially when added prior to drug treatment. Similar trend was reflected in induction of programmed cell death. Thus the phytochemical curcumin may enhance the potency of IM used in leukemia therapy, thereby suggesting its role in an adjuvant therapy for CML. 

Keywords: Chronic myelogenous leukemia,imatinib mesylate, curcumin,cytokines,

Download this article as Download

How to cite this article:

Mukherjee, A., R. Sarkar, S. Mukherjee, J. Biswas and Roy, M. 2016. Curcumin Boosts up the Efficacy of Imatinib Mesylate in Chronic Myelogenic Leukemia Cell Line K-562 by Modulation of Various Markers.Int.J.Curr.Microbiol.App.Sci. 5(12): 240-255. doi:
Copyright: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license.